HealthMedica / MedQuest Announce Strategic National Partnership

November 17, 2014 03:47 AM Eastern Standard Time

SAN FRANCISCO--(BUSINESS WIRE)--Further defining the future of Age Intervention Medicine™, Nathan
Sassover, CEO of HealthMedica Inc., today announced a national
partnership with MedQuest of North Salt Lake Utah. The Agreement was
confirmed by Jeffery Bray, Chief Executive Officer and Christopher
Cantwell, Chief Operating Officer.

Founded in 1996, MedQuest is a long established compounding
pharmaceutics group licensed in all 50 states and Puerto Rico
acknowledged as one of the largest custom prescription centers in the US
among 7,500 pharmacies nationwide.

Chris Cantwell, MedQuest COO commented: “We are pleased to have been
selected by HealthMedica and health science visionary Nathan Sassover as
the compounding pharmaceutics provider to support HealthMedica’s
announced rollout of Longevity Medical Centers nationwide.”

HealthMedica (www.Healthmedica.com)
and its affiliated clinical partners define a transformative model
advancing both preventive and interventional therapeutics.
HealthMedica’s focus is on Age Management Therapeutics™, a proprietary
series of protocols which originated in 2002, and have demonstrated
evidence-based clinically validated therapeutic platforms which also
integrate the dynamics of Quality of Life aspects within the totality of
proactive age intervention.

About Nathan Sassover

Nathan Sassover’s cross-industry innovations, patented inventions and
discoveries extend to diverse technology venues ranging from
micro-electronics to health sciences to advanced internet broadcast
network architecture. His leading edge innovations and patents have
created several technology and business sectors, including the
multi-billion dollar global Automotive Remote Keyless Security industry.

In the field of life sciences, Nathan Sassover’s discoveries have
resulted in medical and therapeutic platforms and clinical developments
addressing the neurobiology of aging and disease as well as molecular
cancer genetics and DNA programmable pharmaceutics conjoining
Neurosystemic Medicine and Epigenetic Therapeutics.